The burden of residual CV risk in the statin era
Video navigation menu
- Residual risk despite agressive LDL-c lowering 01:07
- Residual risk: targeting obesity and novel antidiabetes agents 02:31
- Residual risk: further reduction of LDL-c and targeting inflammation 05:08
- Residual risk: targeting triglycerides and Lp(a) 07:09
This video was recorded as part of the two-day meeting 'Current Challenges in Lipid Management and Cardiovascular Risk Reduction' at Brigham and Women's Hospital/Harvard Medical School in Boston, MA, USA on October 31 2019.
Erin Bohula, MD is cardiologist at the Brigham and Women's Hospital and investigator of the TIMI study group in Boston, MA, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.